Estradiol
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vulvar Atrophy
Conditions
Vulvar Atrophy, Vaginal Atrophy
Trial Timeline
Nov 6, 2012 → Apr 30, 2013
NCT ID
NCT01753102About Estradiol
Estradiol is a phase 3 stage product being developed by Sun Pharmaceutical for Vulvar Atrophy. The current trial status is terminated. This product is registered under clinical trial identifier NCT01753102. Target conditions include Vulvar Atrophy, Vaginal Atrophy.
What happened to similar drugs?
0 of 1 similar drugs in Vulvar Atrophy were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01753102 | Phase 3 | Terminated |
Competing Products
7 competing products in Vulvar Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tacrolimus cream + Clobetasol cream | Astellas Pharma | Phase 2 | 35 |
| Estradiol Vaginal Tablets 10 mcg (Glenmark) + Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk) + Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark) | Glenmark Pharmaceuticals | Phase 3 | 40 |
| Cisplatin + Pembrolizumab | Merck | Phase 2 | 39 |
| Cardunolizumab | Innovent Biologics | Phase 2 | 42 |
| AK104 + AK104+ Paclitaxel+Cisplatin or Carboplatin | Akeso | Phase 2 | 42 |
| AVA6103 | Avacta Group | Phase 1 | 26 |
| VGX-3100 + Imiquimod 5% Cream | Inovio Pharmaceuticals | Phase 2 | 25 |